Clinical Trial Update: Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating durvalumab in combination with intraductal radiofrequency ablation for unresectable extrahepatic cholangiocarcinoma is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Distal Cholangiocarcinoma
• Extrahepatic Cholangiocarcinoma
• Perihilar Cholangiocarcinoma

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Conditions: Extrahepatic Cholangiocarcinoma, Unresectable Perihilar or Ductal CCA | Phase 2 | Status: RECRUITING